Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

Posted: November 22, 2021 at 1:57 am

Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties on net sales of commercialized products

Read more from the original source:
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

Related Posts